Swedbank AB Purchases 6,534 Shares of Humana Inc. $HUM

Swedbank AB lifted its position in Humana Inc. (NYSE:HUM) by 6.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 111,803 shares of the insurance provider’s stock after purchasing an additional 6,534 shares during the quarter. Swedbank AB’s holdings in Humana were worth $28,636,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of Humana by 4.1% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 250,330 shares of the insurance provider’s stock worth $66,207,000 after purchasing an additional 9,960 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd increased its holdings in shares of Humana by 1.8% in the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 16,118 shares of the insurance provider’s stock worth $4,128,000 after purchasing an additional 286 shares during the last quarter. Pinnacle Wealth Management Advisory Group LLC increased its holdings in shares of Humana by 12.6% in the fourth quarter. Pinnacle Wealth Management Advisory Group LLC now owns 945 shares of the insurance provider’s stock worth $242,000 after purchasing an additional 106 shares during the last quarter. Montag A & Associates Inc. increased its holdings in shares of Humana by 1,880.0% in the fourth quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock worth $25,000 after purchasing an additional 94 shares during the last quarter. Finally, CENTRAL TRUST Co increased its stake in Humana by 36.5% during the fourth quarter. CENTRAL TRUST Co now owns 273 shares of the insurance provider’s stock worth $70,000 after acquiring an additional 73 shares during the last quarter. 92.38% of the stock is owned by institutional investors.

Humana Stock Up 0.4%

Shares of NYSE HUM opened at $247.28 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.77 and a current ratio of 1.77. The firm has a market capitalization of $29.69 billion, a price-to-earnings ratio of 26.45, a PEG ratio of 2.27 and a beta of 0.68. The stock has a 50 day moving average price of $192.18 and a 200 day moving average price of $226.48. Humana Inc. has a 52-week low of $163.11 and a 52-week high of $315.35.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, April 29th. The insurance provider reported $10.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.97 by $0.34. The firm had revenue of $39.65 billion during the quarter, compared to analyst estimates of $39.37 billion. Humana had a return on equity of 10.45% and a net margin of 0.82%.Humana’s quarterly revenue was up 23.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $11.58 earnings per share. Humana has set its FY 2026 guidance at 9.000- EPS. Sell-side analysts expect that Humana Inc. will post 9.06 earnings per share for the current year.

Humana Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Friday, June 26th will be issued a $0.885 dividend. The ex-dividend date is Friday, June 26th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.4%. Humana’s payout ratio is presently 37.86%.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on HUM. UBS Group boosted their price objective on Humana from $195.00 to $262.00 and gave the stock a “neutral” rating in a research note on Thursday, April 30th. Weiss Ratings reissued a “sell (d+)” rating on shares of Humana in a research note on Tuesday, April 21st. Mizuho boosted their price objective on Humana from $258.00 to $290.00 in a research note on Thursday, April 30th. Wells Fargo & Company boosted their price objective on Humana from $206.00 to $227.00 and gave the stock an “equal weight” rating in a research note on Tuesday, April 7th. Finally, Wolfe Research decreased their price target on Humana from $325.00 to $250.00 and set an “outperform” rating for the company in a research note on Monday, April 6th. Seven research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Humana presently has a consensus rating of “Hold” and an average price target of $247.61.

Insider Activity

In other news, insider Sanjay K. Shetty purchased 810 shares of the stock in a transaction that occurred on Monday, February 23rd. The stock was purchased at an average price of $185.21 per share, for a total transaction of $150,020.10. Following the completion of the acquisition, the insider owned 11,657 shares of the company’s stock, valued at approximately $2,158,992.97. This trade represents a 7.47% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.20% of the company’s stock.

Humana Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.